"Whether it's Dolantin or Chlorpromazine, neither can be used frequently. They have extremely strong side effects.
They use drugs to block the body's ability to control and regulate its temperature, which also causes bodily harm. They can only be used as a treatment.
At the same time, their duration is very short—only three to five days.
The low-temperature Human Hibernation Technology we want to develop relies solely on ultrasound and does not harm the human body. It achieves its effects by activating nerves and genes related to mammalian hibernation. Its duration ranges from five to ten days.
Compared to Human Hibernation treatment, it has far greater potential and commercial value."
A representative from Sequoia Capital took the microphone. "Dr. Chen, I'm very interested in the commercial value you just mentioned.
How do you view the commercial value of this technology? At present, immigration to Mars seems far in the future, while a trip to the Moon wouldn't take that long. So where does your technology's commercial value lie?"
Chen Yuanguang said, "There are several main aspects. First, we can replace traditional hibernation therapy.
We can also apply it to ocean shipping and long-haul passenger flights. The five to ten days I just mentioned is the maximum duration, and the waking time is controllable.
For long-haul flights lasting more than a day, passengers could enter hibernation as soon as they boarded. When they woke up, they would have arrived at their destination."
The Sequoia Capital representative said, "Both are widely applicable scenarios, though the latter depends on the size of your equipment—or rather, the instrument.
And whether it requires supporting measures.
Are we talking about a limited-size, limited-weight ultrasound device that can be set to turn on and off automatically, or would it require a whole range of supporting facilities?"
Chen